Selective BRAFV600E Inhibitor PLX4720, Requires TRAIL Assistance to Overcome Oncogenic PIK3CA Resistance

Documented sensitivity of melanoma cells to PLX4720, a selective BRAFV600E inhibitor, is based on the presence of mutant BRAF(V600E) alone, while wt-BRAF or mutated KRAS result in cell proliferation. In colon cancer appearance of oncogenic alterations is complex , since BRAF, like KRAS mutations, te...

Descripción completa

Detalles Bibliográficos
Autores principales: Oikonomou, Eftychia, Koc, Michal, Sourkova, Vladimira, Andera, Ladislav, Pintzas, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124547/
https://www.ncbi.nlm.nih.gov/pubmed/21738740
http://dx.doi.org/10.1371/journal.pone.0021632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124547/
https://www.ncbi.nlm.nih.gov/pubmed/21738740
http://dx.doi.org/10.1371/journal.pone.0021632

Ejemplares similares